ArticleWorld journal of oncology2025
MiR-301a-3p Promotes Triple-Negative Breast Cancer Progression via PTEN Suppression in Tumor Cells and the Microenvironment.
Article in World journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype, poses a severe threat to women's health. Adipose-derived stem cells (ADSCs) and microRNAs (miRNAs) critically influence tumor progression within the tumor microenvironment (TME), but the role of the miR-301a-3p/PTEN axis in TNBC requires elucidation. Methods: PTEN expression and effects were assessed by comparing clinical TNBC tissues with adjacent normal tissues. Mechanisms were investigated using integrated dataset analysis, luciferase reporter assays, functional cell experiments (assessing malignant phenotypes), co-culture models with ADSCs, and Results: MiR-301a-3p was upregulated in TNBC and directly bound PTEN's 3'-UTR to suppress its expression. Functionally, miR-301a-3p enhanced tumor cell malignancy. Tumor cell-derived exosomes transported miR-301a-3p to ADSCs in the TME, suppressing PTEN, activating the PI3K/AKT pathway, and upregulating VEGFA secretion. Conclusion: MiR-301a-3p drives TNBC progression via exosome-mediated crosstalk with ADSCs, forming a PTEN/PI3K/AKT/VEGFA signaling axis. It represents a promising therapeutic target and novel biomarker with significant clinical value for TNBC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.